Lentigen and the University of Pennsylvania Enter License Agreement for Lentiviral Vector Technology

Lentigen Corporation has announced an exclusive, worldwide licensing agreement with the University of Pennsylvania relating to lentiviral vector technology.

The intellectual property, which was developed at Penn's School of Medicine, has been granted to Lentigen to develop and commercialize products for both research reagents for laboratory research purposes and potentially, therapeutic purposes.    

Dr. Boro Dropulic, Founder and CEO of Lentigen, commented, "Lentigen's license agreement with the University of Pennsylvania is part of our goal to continue licensing lentiviral technology from both academic research institutions and the private sector, which we will then work to commercialize."